Cargando…
Aggregation risk prediction for antibodies and its application to biotherapeutic development
Aggregation is a common problem affecting biopharmaceutical development that can have a significant effect on the quality of the product, as well as the safety to patients, particularly because of the increased risk of immune reactions. Here, we describe a new high-throughput screening algorithm dev...
Autores principales: | Obrezanova, Olga, Arnell, Andreas, de la Cuesta, Ramón Gómez, Berthelot, Maud E, Gallagher, Thomas RA, Zurdo, Jesús, Stallwood, Yvette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622581/ https://www.ncbi.nlm.nih.gov/pubmed/25760769 http://dx.doi.org/10.1080/19420862.2015.1007828 |
Ejemplares similares
-
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
por: Zurdo, Jesús, et al.
Publicado: (2015) -
IgY Antibodies as Biotherapeutics in Biomedicine
por: León-Núñez, Diana, et al.
Publicado: (2022) -
Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates
por: Hong, Paula, et al.
Publicado: (2012) -
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023) -
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
por: Husain, Bushra, et al.
Publicado: (2018)